Risk of Prostate Cancer Progression with PSA Below 0.18 ng/mL for 15 Months
A PSA maintained below 0.18 ng/mL for 15 consecutive months does not meet the definition of biochemical recurrence and indicates an extremely low risk of cancer progression during this surveillance period. 1, 2
Understanding Biochemical Recurrence Thresholds
The American Urological Association defines biochemical recurrence after radical prostatectomy as two consecutive PSA measurements ≥ 0.2 ng/mL. 1, 2 Your PSA level of <0.18 ng/mL falls below this threshold and therefore does not constitute biochemical recurrence. 2
- The most commonly used PSA cutpoint for defining recurrence after prostatectomy is 0.2 ng/mL, used in 35 of 145 studies reviewed by the AUA. 1
- A PSA remaining below 0.2 ng/mL for 15 months indicates no biochemical evidence of recurrence. 2
- Approximately 8.8% of men exhibit a detectable but stable PSA for ≥10 years without any clinical progression, demonstrating that low stable PSA values do not necessarily indicate active disease. 2
Risk Stratification Based on Your PSA Pattern
Your risk of cancer progression is very low based on the following evidence:
- PSA levels below 0.2 ng/mL maintained over 15 months do not trigger any salvage therapy recommendations. 1, 2
- The 5-year biochemical failure rate after salvage radiotherapy for patients with PSA <0.2 ng/mL is only 26.6%, and this applies to patients who already met the recurrence definition—you have not. 1
- PSA doubling time (PSADT) ≥15 months is associated with a low likelihood of prostate cancer-specific mortality over 10 years. 2
Rare Exception: PSA-Independent Progression
While extremely uncommon, cancer progression can rarely occur with undetectable or very low PSA levels. 3 However, this scenario has specific characteristics that likely do not apply to your situation:
- PSA-independent progression occurs almost exclusively in patients with aggressive histologic variants (small cell carcinoma, ductal, or sarcomatoid features), present in 46% of such cases. 3
- 85% of patients with PSA-independent progression had Gleason scores ≥7,63% had clinical T3/T4 tumors, and 41% had pretreatment PSA >10 ng/mL. 3
- Eight of 10 patients who progressed with undetectable PSA had small cell carcinoma. 3
If your original pathology showed conventional adenocarcinoma without atypical variants, this risk is negligible. 3
Recommended Surveillance Strategy
Continue monitoring with the following approach:
- Repeat PSA testing every 3 months to verify stability and detect any upward trend. 2
- Perform digital rectal examination at each follow-up visit to assess for palpable local recurrence. 2
- Do not initiate salvage therapy before confirming biochemical recurrence (two consecutive PSA ≥0.2 ng/mL), as premature intervention exposes you to unnecessary toxicity without proven benefit. 2
When to Escalate Evaluation
Salvage radiotherapy should only be considered if:
- Two consecutive PSA measurements reach ≥0.2 ng/mL (meeting the BCR definition). 1, 2
- PSA begins rising consistently with a PSADT <15 months, indicating more aggressive disease biology. 2
- PSA reaches 0.5 ng/mL, the optimal threshold for maximal salvage radiotherapy efficacy. 1
Critical Pitfalls to Avoid
- Do not switch PSA assay platforms during surveillance; inter-method bias can range from –24% to +21%, creating false trends. 4
- Do not order bone scintigraphy at your current PSA level; it has very low diagnostic yield when PSA is <10 ng/mL. 2
- Do not assume a single elevated PSA represents true recurrence; biological variation is common and requires confirmation with repeat testing. 2, 5
Bottom Line
With PSA maintained below 0.18 ng/mL for 15 months, you have no biochemical evidence of recurrence and an extremely low risk of cancer progression. 1, 2 Continue quarterly PSA monitoring and clinical examination. Only if PSA rises to meet the recurrence definition (≥0.2 ng/mL on two consecutive tests) should salvage therapy be considered. 1, 2